EVENTS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London
SOUTH SAN FRANCISCO, Calif., March. 4, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 8, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma to Participate in the 31st Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro’s CEO, Bill Newell was Live Today on TD Ameritrade, The Watch List
Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – PowerPoint Presentation
To download, Click Here
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster
Antitumor activity of STRO-002, a novel anti-folate receptor -⍺ (FolR⍺) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC) Please Click the Link, AACR...
Sutro Biopharma to Present at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer - Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer...
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – STRO-002 – Abstract
Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC) Denise Uyar, 1 Russell J...